Abstract
Steroid hormones intricately shape the landscape of cancer in breast, prostate, ovarian, and endometrial tissues, playing a pivotal role in tumorigenesis and progression. The dynamic interplay between these hormones and cancer cells reveals a nuanced relationship where steroid hormones can both promote and inhibit cancer progression. Understanding the complex nature of this interaction is vital for unraveling the intricacies of tumor development in these hormone-driven malignancies. Dysregulation in steroid hormone signaling pathways is a key driver, contributing to the pathophysiology of hormone-driven cancers. The chapter delves into the multifaceted nature of steroid hormones and their dual impact on tumorigenesis. The therapeutic landscape for these cancers has been significantly influenced by insights into steroid hormone dynamics. Hormonal treatments, such as those tailored for breast and prostate cancers, exemplify strategies aimed at manipulating steroid hormone actions to impede cancer progression. However, the narrative is complex, with cancer cells being able to exploit steroid hormones, reminiscent of evasion mechanisms observed in the contexts of other cancers. This chapter comprehensively explores the intricate relationship between steroid hormones and cancers of the breast, prostate, ovarian, and endometrial tissues.
This is a preview of subscription content, log in via an institution to check access.
References
Abu Shahin N, Aladily T, Abu Alhaj N, Al-Khader A, Alqaqa S, Aljaberi R et al (2021) Differential expression of androgen receptor in type I and type II endometrial carcinomas: a Clinicopathological analysis and correlation with outcome. Oman Med J 36(2):e245. https://doi.org/10.5001/omj.2021.53
Adamo P, Ladomery MR (2016) The oncogene ERG: a key factor in prostate cancer. Oncogene 35(4):403–414. https://doi.org/10.1038/onc.2015.109
Adhya D, Annuario E, Lancaster MA, Price J, Baron-Cohen S, Srivastava DP (2018) Understanding the role of steroids in typical and atypical brain development: advantages of using a “brain in a dish” approach. J Neuroendocrinol 30(2). https://doi.org/10.1111/jne.12547
Agarwal N, Hahn AW, Gill DM, Farnham JM, Poole AI, Cannon-Albright L (2017) Independent validation of effect of HSD3B1 genotype on response to androgen-deprivation therapy in prostate cancer. JAMA Oncol 3(6):856–857. https://doi.org/10.1001/jamaoncol.2017.0147
Anestis A, Zoi I, Papavassiliou AG, Karamouzis MV (2020) Androgen receptor in breast cancer-clinical and preclinical research insights. Molecules 25(2). https://doi.org/10.3390/molecules25020358
Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD et al (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309–1322. https://doi.org/10.1016/j.cell.2013.11.012
Arora T, Mullangi S, Lekkala MR (2023) Ovarian cancer. StatPearls Publishing, Treasure Island. Copyright © 2023, StatPearls Publishing LLC
Asuthkar S, Velpula KK, Elustondo PA, Demirkhanyan L, Zakharian E (2015) TRPM8 channel as a novel molecular target in androgen-regulated prostate cancer cells. Oncotarget 6(19):17221–17236. https://doi.org/10.18632/oncotarget.3948
Auchus RJ (2004) The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 15(9):432–438. https://doi.org/10.1016/j.tem.2004.09.004
Awad D, Pulliam TL, Lin C, Wilkenfeld SR, Frigo DE (2018) Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches. Curr Opin Pharmacol 41:1–11. https://doi.org/10.1016/j.coph.2018.03.002
Bamberger AM, Milde-Langosch K, Löning T, Bamberger CM (2001) The glucocorticoid receptor is specifically expressed in the stromal compartment of the human endometrium. J Clin Endocrinol Metab 86(10):5071–5074. https://doi.org/10.1210/jcem.86.10.8101
Banerjee PP, Banerjee S, Brown TR, Zirkin BR (2018) Androgen action in prostate function and disease. Am J Clin Exp Urol 6(2):62–77
Bánhegyi G, Csala M, Benedetti A (2009) Hexose-6-phosphate dehydrogenase: linking endocrinology and metabolism in the endoplasmic reticulum. J Mol Endocrinol 42(4):283–289. https://doi.org/10.1677/jme-08-0156
Beral V, Bull D, Green J, Reeves G (2007) Ovarian cancer and hormone replacement therapy in the million women study. Lancet 369(9574):1703–1710. https://doi.org/10.1016/s0140-6736(07)60534-0
Blanchard Z, Vahrenkamp JM, Berrett KC, Arnesen S, Gertz J (2019) Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer. Genome Res 29(9):1429–1441. https://doi.org/10.1101/gr.244780.118
Bonkhoff H (2018) Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression. Prostate 78(1):2–10. https://doi.org/10.1002/pros.23446
Bonkhoff H, Berges R (2009) The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 55(3):533–542. https://doi.org/10.1016/j.eururo.2008.10.035
Bosland MC (2000) The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 27:39–66. https://doi.org/10.1093/oxfordjournals.jncimonographs.a024244
Bosland MC, Ford H, Horton L (1995) Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis 16(6):1311–1317. https://doi.org/10.1093/carcin/16.6.1311
Broustas CG, Hopkins KM, Panigrahi SK, Wang L, Virk RK, Lieberman HB (2019) RAD9A promotes metastatic phenotypes through transcriptional regulation of anterior gradient 2 (AGR2). Carcinogenesis 40(1):164–172. https://doi.org/10.1093/carcin/bgy131
Bulletti C, Bulletti FM, Sciorio R, Guido M (2022) Progesterone: the Key factor of the beginning of life. Int J Mol Sci 23(22). https://doi.org/10.3390/ijms232214138
Cable JK, Grider MH (2023) Physiology, progesterone. StatPearls Publishing, Treasure Island. Copyright © 2023, StatPearls Publishing LLC
Biomed Res Int 2016:8909878. https://doi.org/10.1155/2016/8909878
Cairat M, Al Rahmoun M, Gunter MJ, Heudel PE, Severi G, Dossus L, Fournier A (2021) Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women. BMC Med 19(1):186. https://doi.org/10.1186/s12916-021-02004-6
Cao L, Xu C, **ang G, Liu F, Liu X, Li C et al (2018) AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer. Mol Cancer 17(1):136. https://doi.org/10.1186/s12943-018-0883-0
Carson-Jurica MA, Schrader WT, O’Malley BW (1990) Steroid receptor family: structure and functions. Endocr Rev 11(2):201–220. https://doi.org/10.1210/edrv-11-2-201
Cavalieri EL, Rogan EG (2011) Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol 125(3–5):169–180. https://doi.org/10.1016/j.jsbmb.2011.03.008
Chang CY, McDonnell DP (2012) Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeutic target in cancer. Clin Cancer Res 18(22):6089–6095. https://doi.org/10.1158/1078-0432.Ccr-11-3221
Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J et al (2013) A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154(5):1074–1084. https://doi.org/10.1016/j.cell.2013.07.029
Chang YC, Chen CK, Chen MJ, Lin JC, Lin CH, Huang WC et al (2017) Expression of 3β-Hydroxysteroid dehydrogenase type 1 in breast cancer is associated with poor prognosis independent of estrogen receptor status. Ann Surg Oncol 24(13):4033–4041. https://doi.org/10.1245/s10434-017-6000-6
Chen WY (2008) Exogenous and endogenous hormones and breast cancer. Best Pract Res Clin Endocrinol Metab 22(4):573–585. https://doi.org/10.1016/j.beem.2008.08.001
Chen YX, Wang Y, Fu CC, Diao F, Song LN, Li ZB et al (2010) Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells. Endocr Relat Cancer 17(1):39–50. https://doi.org/10.1677/erc-08-0296
Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R et al (2015) Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res 21(6):1273–1280. https://doi.org/10.1158/1078-0432.Ccr-14-1220
Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72(1–2):23–27. https://doi.org/10.1016/s0960-0760(00)00040-6
Christoforou P, Christopoulos PF, Koutsilieris M (2014) The role of estrogen receptor β in prostate cancer. Mol Med 20(1):427–434. https://doi.org/10.2119/molmed.2014.00105
Ciucci A, Zannoni GF, Buttarelli M, Lisi L, Travaglia D, Martinelli E et al (2016) Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers. Oncotarget 7(7):8155–8171. https://doi.org/10.18632/oncotarget.6943
Cleary MP, Grossmann ME (2009) Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 150(6):2537–2542. https://doi.org/10.1210/en.2009-0070
Clusan L, Le Goff P, Flouriot G, Pakdel F (2021) A closer look at estrogen receptor mutations in breast cancer and their implications for estrogen and antiestrogen responses. Int J Mol Sci 22(2). https://doi.org/10.3390/ijms22020756
Clusan L, Ferrière F, Flouriot G, Pakdel F (2023) A basic review on estrogen receptor signaling pathways in breast cancer. Int J Mol Sci 24(7). https://doi.org/10.3390/ijms24076834
Conlon N, Leitao MM Jr, Abu-Rustum NR, Soslow RA (2014) Grading uterine endometrioid carcinoma: a proposal that binary is best. Am J Surg Pathol 38(12):1583–1587. https://doi.org/10.1097/pas.0000000000000327
Cookman CJ, Belcher SM (2015) Estrogen receptor-β up-regulates IGF1R expression and activity to inhibit apoptosis and increase growth of Medulloblastoma. Endocrinology 156(7):2395–2408. https://doi.org/10.1210/en.2015-1141
Cousins FL, Pandoy R, ** S, Gargett CE (2021) The elusive endometrial epithelial stem/progenitor cells. Front Cell Dev Biol 9:640319. https://doi.org/10.3389/fcell.2021.640319
Coutinho I, Day TK, Tilley WD, Selth LA (2016) Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer 23(12):T179–t197. https://doi.org/10.1530/erc-16-0422
Csaba G (2014) Hormones in the immune system and their possible role. A critical review. Acta Microbiol Immunol Hung 61(3):241–260. https://doi.org/10.1556/AMicr.61.2014.3.1
Dai C, Ellisen LW (2023) Revisiting androgen receptor signaling in breast cancer. Oncologist 28(5):383–391. https://doi.org/10.1093/oncolo/oyad049
Dai C, Heemers H, Sharifi N (2017) Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med 7(9). https://doi.org/10.1101/cshperspect.a030452
Di Donato V, Iacobelli V, Schiavi MC, Colagiovanni V, Pecorella I, Palaia I et al (2018) Impact of hormone receptor status and Ki-67 expression on disease-free survival in patients affected by high-risk endometrial cancer. Int J Gynecol Cancer 28(3):505–513. https://doi.org/10.1097/igc.0000000000001191
Diep CH, Ahrendt H, Lange CA (2016) Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER/PR target genes. Steroids 114:48–58. https://doi.org/10.1016/j.steroids.2016.09.004
Doan TB, Cheung V, Clyne CD, Hilton HN, Eriksson N, Young MJ et al (2020) A tumour suppressive relationship between mineralocorticoid and retinoic acid receptors activates a transcriptional program consistent with a reverse Warburg effect in breast cancer. Breast Cancer Res 22(1):122. https://doi.org/10.1186/s13058-020-01355-x
Droog M, Nevedomskaya E, Kim Y, Severson T, Flach KD, Opdam M et al (2016) Comparative Cistromics reveals genomic cross-talk between FOXA1 and ERα in tamoxifen-associated endometrial carcinomas. Cancer Res 76(13):3773–3784. https://doi.org/10.1158/0008-5472.Can-14-1813
du Toit T, Bloem LM, Quanson JL, Ehlers R, Serafin AM, Swart AC (2017) Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC(2)-MS/MS quantification of 11β-hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone. J Steroid Biochem Mol Biol 166:54–67. https://doi.org/10.1016/j.jsbmb.2016.06.009
Eaton NE, Reeves GK, Appleby PN, Key TJ (1999) Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 80(7):930–934. https://doi.org/10.1038/sj.bjc.6690445
Edwards DP (2000) The role of coactivators and corepressors in the biology and mechanism of action of steroid hormone receptors. J Mammary Gland Biol Neoplasia 5(3):307–324. https://doi.org/10.1023/a:1009503029176
Ehsani M, David FO, Baniahmad A (2021) Androgen receptor-dependent mechanisms mediating drug resistance in prostate cancer. Cancers (Basel) 13(7). https://doi.org/10.3390/cancers13071534
Eick GN, Colucci JK, Harms MJ, Ortlund EA, Thornton JW (2012) Evolution of minimal specificity and promiscuity in steroid hormone receptors. PLoS Genet 8(11):e1003072. https://doi.org/10.1371/journal.pgen.1003072
Ellem SJ, Risbridger GP (2006) Aromatase and prostate cancer. Minerva Endocrinol 31(1):1–12
Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N (2010) 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 151(8):3514–3520. https://doi.org/10.1210/en.2010-0138
Eyster K (2016) The estrogen receptors: an overview from different perspectives. (pp. 1-10). https://doi.org/10.1007/978-1-4939-3127-9_1
Fagan DH, Yee D (2008) Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13(4):423–429. https://doi.org/10.1007/s10911-008-9098-0
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L et al (2018) Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 5(2):77–106. https://doi.org/10.1016/j.gendis.2018.05.001
Fentiman I (2009) Male breast cancer: a review. Ecancermedicalscience 3:140. https://doi.org/10.3332/ecancer.2009.140
Fiandalo MV, Wilton J, Mohler JL (2014) Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment. Int J Biol Sci 10(6):596–601. https://doi.org/10.7150/ijbs.8780
Filardo EJ, Thomas P (2005) GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 16(8):362–367. https://doi.org/10.1016/j.tem.2005.08.005
Folkerd EJ, Dowsett M (2010) Influence of sex hormones on cancer progression. J Clin Oncol 28(26):4038–4044. https://doi.org/10.1200/jco.2009.27.4290
Foradori CD, Weiser MJ, Handa RJ (2008) Non-genomic actions of androgens. Front Neuroendocrinol 29(2):169–181. https://doi.org/10.1016/j.yfrne.2007.10.005
Formby B, Wiley TS (1998) Progesterone inhibits growth and induces apoptosis in breast cancer cells: inverse effects on Bcl-2 and p53. Ann Clin Lab Sci 28(6):360–369
Fuentes N, Silveyra P (2019) Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol 116:135–170. https://doi.org/10.1016/bs.apcsb.2019.01.001
Gajjar K, Ogden G, Mujahid MI, Razvi K (2012) Symptoms and risk factors of ovarian cancer: a survey in primary care. ISRN Obstet Gynecol 2012:754197. https://doi.org/10.5402/2012/754197
Garabedian MJ, Yamamoto KR (1992) Genetic dissection of the signaling domain of a mammalian steroid receptor in yeast. Mol Biol Cell 3(11):1245–1257. https://doi.org/10.1091/mbc.3.11.1245
Garcia Gil S, Ramos Rodriguez R, Plata Bello A, Nazco Casariego G, Garcia Marrero R, Cruz Jurado J et al (2018) Relationship between mutations in the HSD3B1 gene and response time to androgen deprivation therapy in the treatment of prostate cancer. Eur Soc Oncol Pharm:25–27
Gibson E, Mahdy H (2023) Anatomy, abdomen and pelvis, ovary. StatPearls Publishing, Treasure Island. Copyright © 2023, StatPearls Publishing LLC
Giona S (2021) The epidemiology of prostate cancer. In: Bott SRJ, Ng KL (eds) Prostate cancer. Exon Publications, Brisbane (AU). Copyright: The Authors. doi:10.36255/exonpublications.prostatecancer.epidemiology.2021
Guerini-Rocco E, Gray KP, Fumagalli C, Reforgiato MR, Leone I, Rafaniello Raviele P et al (2021) Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: results from the SOLE trial. Clin Cancer Res 27(2):504–512. https://doi.org/10.1158/1078-0432.Ccr-20-0126
Guo J, Ma K, **a HM, Chen QK, Li L, Deng J et al (2018) Androgen receptor reverts dexamethasone-induced inhibition of prostate cancer cell proliferation and migration. Mol Med Rep 17(4):5887–5893. https://doi.org/10.3892/mmr.2018.8566
Hagiwara M, Yasumizu Y, Yamashita N, Rajabi H, Fushimi A, Long MD et al (2021) MUC1-C activates the BAF (mSWI/SNF) complex in prostate cancer stem cells. Cancer Res 81(4):1111–1122. https://doi.org/10.1158/0008-5472.Can-20-2588
Han KH, Kim MK, Kim HS, Chung HH, Song YS (2013) Protective effect of progesterone during pregnancy against ovarian cancer. J Cancer Prev 18(2):113–122. https://doi.org/10.15430/jcp.2013.18.2.113
Handelsman DJ (2000) Androgen physiology, pharmacology, use and misuse. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E et al (eds) Endotext. MDText.com, Inc, South Dartmouth. Copyright © 2000–2023, MDText.com, Inc.
Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6(2):76–85. https://doi.org/10.1038/ncpuro1296
Hashmi AA, Hussain ZF, Qadri A, Irfan M, Ramzan S, Faridi N et al (2018) Androgen receptor expression in endometrial carcinoma and its correlation with clinicopathologic features. BMC Res Notes 11(1):289. https://doi.org/10.1186/s13104-018-3403-9
Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH et al (2016) HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 17(10):1435–1444. https://doi.org/10.1016/s1470-2045(16)30227-3
Hearn JWD, **e W, Nakabayashi M, Almassi N, Reichard CA, Pomerantz M et al (2018) Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer. JAMA Oncol 4(4):558–562. https://doi.org/10.1001/jamaoncol.2017.3164
Hernández-Hernández OT, González-García TK, Camacho-Arroyo I (2012) Progesterone receptor and SRC-1 participate in the regulation of VEGF, EGFR and cyclin D1 expression in human astrocytoma cell lines. J Steroid Biochem Mol Biol 132(1–2):127–134. https://doi.org/10.1016/j.jsbmb.2012.04.005
Herr I, Pfitzenmaier J (2006) Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 7(5):425–430. https://doi.org/10.1016/s1470-2045(06)70694-5
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38(24):2782–2797. https://doi.org/10.1200/jco.20.01296
Hevir N, Trošt N, Debeljak N, Rižner TL (2011) Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines. Chem Biol Interact 191(1–3):206–216. https://doi.org/10.1016/j.cbi.2010.12.013
Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D et al (2021) The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer. Nat Med 27(2):310–320. https://doi.org/10.1038/s41591-020-01168-7
Hiller-Sturmhöfel S, Bartke A (1998) The endocrine system: an overview. Alcohol Health Res World 22(3):153–164
Ho SM (2003) Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 1:73. https://doi.org/10.1186/1477-7827-1-73
Hormones and Breast Cancer (2004) Hum. Reprod Update 10(4):281–293. https://doi.org/10.1093/humupd/dmh025
Hou Z, Huang S, Mei Z, Chen L, Guo J, Gao Y et al (2022) Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer. Cell Rep Med 3(3):100561. https://doi.org/10.1016/j.xcrm.2022.100561
Hsing AW, Chu LW, Stanczyk FZ (2008) Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prev 17(10):2525–2530. https://doi.org/10.1158/1055-9965.Epi-08-0448
Hu J, Zhang Z, Shen WJ, Azhar S (2010) Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab (Lond) 7:47. https://doi.org/10.1186/1743-7075-7-47
Huggins C, Hodges CV (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate*. Cancer Res 1(4):293–297
Iacopetta D, Rechoum Y, Fuqua SAW (2012) The role of androgen receptor in breast cancer. Drug Disc Today Dis Mech 9(1):e19–e27. https://doi.org/10.1016/j.ddmec.2012.11.003
Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ et al (2014) Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer 5(2):72–89. https://doi.org/10.1007/s12672-014-0173-2
Jacobsen BM, Horwitz KB (2012) Progesterone receptors, their isoforms and progesterone regulated transcription. Mol Cell Endocrinol 357(1–2):18–29. https://doi.org/10.1016/j.mce.2011.09.016
Jeon SY, Hwang KA, Choi KC (2016) Effect of steroid hormones, estrogen and progesterone, on epithelial mesenchymal transition in ovarian cancer development. J Steroid Biochem Mol Biol 158:1–8. https://doi.org/10.1016/j.jsbmb.2016.02.005
Jeong HM, Kwon MJ, Shin YK (2014) Overexpression of cancer-associated genes via epigenetic derepression mechanisms in gynecologic cancer. Front Oncol 4:12. https://doi.org/10.3389/fonc.2014.00012
Johnson KS, Conant EF, Soo MS (2020) Molecular subtypes of breast cancer: a review for breast radiologists. J Breast Imag 3(1):12–24. https://doi.org/10.1093/jbi/wbaa110
Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E (2015) Breast cancer risk factors. Prz Menopauzalny 14(3):196–202. https://doi.org/10.5114/pm.2015.54346
Kariagina A, Aupperlee MD, Haslam SZ (2008) Progesterone receptor isoform functions in normal breast development and breast cancer. Crit Rev Eukaryot Gene Expr 18(1):11–33. https://doi.org/10.1615/critreveukargeneexpr.v18.i1.20
Keightley M-C (1998) Steroid receptor isoforms: exception or rule? Mol Cell Endocrinol 137(1):1–5. https://doi.org/10.1016/S0303-7207(97)00236-0
Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D et al (2020) HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. Ann Oncol 31(9):1186–1197. https://doi.org/10.1016/j.annonc.2020.06.006
Kim JJ, Kurita T, Bulun SE (2013) Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 34(1):130–162. https://doi.org/10.1210/er.2012-1043
Kinter KJ, Amraei R, Anekar AA (2023) Biochemistry, dihydrotestosterone. StatPearls Publishing, Treasure Island. Copyright © 2023, StatPearls Publishing LLC
Lee HJ, Lee B, Choi H, Kim T, Kim Y, Kim YB (2023) Impact of hormone replacement therapy on risk of ovarian cancer in postmenopausal women with De novo endometriosis or a history of endometriosis. Cancers (Basel) 15(6). https://doi.org/10.3390/cancers15061708
Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C et al (2007) A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer 110(11):2448–2456. https://doi.org/10.1002/cncr.23072
Li J, Alyamani M, Zhang A, Chang KH, Berk M, Li Z et al (2017) Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer. elife 6. https://doi.org/10.7554/eLife.20183
Li H, Liu Y, Wang Y, Zhao X, Qi X (2021) Hormone therapy for ovarian cancer: emphasis on mechanisms and applications (review). Oncol Rep 46(4). https://doi.org/10.3892/or.2021.8174
Li Z, Wei H, Li S, Wu P, Mao X (2022) The role of progesterone receptors in breast cancer. Drug Des Devel Ther 16:305–314. https://doi.org/10.2147/dddt.S336643
Liao W, Sui X, Hou G, Yang M, Lin Y, Lu J, Yang Q (2023) Trends in estrogen and progesterone receptors in prostate cancer: a bibliometric analysis. Front Oncol 13:1111296. https://doi.org/10.3389/fonc.2023.1111296
Lin CY, Ström A, Vega VB, Kong SL, Yeo AL, Thomsen JS et al (2004) Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol 5(9):R66. https://doi.org/10.1186/gb-2004-5-9-r66
Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411(6835):375–379. https://doi.org/10.1038/35077241
Lorence MC, Murry BA, Trant JM, Mason JI (1990) Human 3 beta-hydroxysteroid dehydrogenase/delta 5----4isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. Endocrinology 126(5):2493–2498. https://doi.org/10.1210/endo-126-5-2493
Lu C, Terbuch A, Dolling D, Yu J, Wang H, Chen Y et al (2020) Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype. Ann Oncol 31(9):1178–1185. https://doi.org/10.1016/j.annonc.2020.04.473
Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A (2021) Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel) 13(17). https://doi.org/10.3390/cancers13174287
Lv C, Sun J, Ye Y, Lin Z, Li H, Liu Y et al (2022) Long noncoding RNA EIF1AX-AS1 promotes endometrial cancer cell apoptosis by affecting EIF1AX mRNA stabilization. Cancer Sci 113(4):1277–1291. https://doi.org/10.1111/cas.15275
Maček P, Molinari N, Sobočan M, Knez J (2023) What role do androgens play in endometrial cancer? J Pers Med 13(2). https://doi.org/10.3390/jpm13020341
Madhu Krishna B, Chaudhary S, Mishra DR, Naik SK, Suklabaidya S, Adhya AK, Mishra SK (2018) Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer. BMC Cancer 18(1):607. https://doi.org/10.1186/s12885-018-4528-x
Mahdi Z, Abdulfatah E, Pardeshi V, Hassan O, Schultz D, Morris R et al (2017) The impact of androgen receptor expression on endometrial carcinoma recurrence and survival. Int J Gynecol Pathol 36(5):405–411. https://doi.org/10.1097/pgp.0000000000000355
Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A (2021) Endometrial cancer. Nat Rev Dis Primers 7(1):88. https://doi.org/10.1038/s41572-021-00324-8
Manning-Geist BL, Gordhandas SB, Giri DD, Iasonos A, Zhou Q, Girshman J et al (2022) Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer. Gynecol Oncol 164(1):12–17. https://doi.org/10.1016/j.ygyno.2021.10.087
Marques P, Skorupskaite K, Rozario KS, Anderson RA, George JT (2000) Physiology of GnRH and gonadotropin secretion. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E et al (eds) Endotext. MDText.com, Inc, South Dartmouth. Copyright © 2000–2023, MDText.com, Inc.
Martin MB, Stoica A (2002) Insulin-like growth factor-I and estrogen interactions in breast cancer. J Nutr 132(12):3799S–3801S. https://doi.org/10.1093/jn/132.12.3799S
Mauvais-Jarvis F, Lange CA, Levin ER (2022) Membrane-initiated estrogen, androgen, and progesterone receptor signaling in health and disease. Endocr Rev 43(4):720–742. https://doi.org/10.1210/endrev/bnab041
McCluggage WG (2011) Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 43(5):420–432. https://doi.org/10.1097/PAT.0b013e328348a6e7
McDonnel AC, Van Kirk EA, Isaak DD, Murdoch WJ (2003) Inhibitory effects of progesterone on plasma membrane fluidity and tumorigenic potential of ovarian epithelial cancer cells. Exp Biol Med (Maywood) 228(3):308–314. https://doi.org/10.1177/153537020322800310
McGlorthan L, Paucarmayta A, Casablanca Y, Maxwell GL, Syed V (2021) Progesterone induces apoptosis by activation of caspase-8 and calcitriol via activation of caspase-9 pathways in ovarian and endometrial cancer cells in vitro. Apoptosis 26(3–4):184–194. https://doi.org/10.1007/s10495-021-01657-1
McHann MC, Blanton HL, Guindon J (2021) Role of sex hormones in modulating breast and ovarian cancer associated pain. Mol Cell Endocrinol 533:111320. https://doi.org/10.1016/j.mce.2021.111320
McKeown AN, Bridgham JT, Anderson DW, Murphy MN, Ortlund EA, Thornton JW (2014) Evolution of DNA specificity in a transcription factor family produced a new gene regulatory module. Cell 159(1):58–68. https://doi.org/10.1016/j.cell.2014.09.003
McManus JM, Vargas R, Bazeley PS, Schumacher FR, Sharifi N (2022) Association between adrenal-restrictive HSD3B1 inheritance and hormone-independent subtypes of endometrial and breast cancer. JNCI Cancer Spectr 6(5). https://doi.org/10.1093/jncics/pkac061
McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H (2013) Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 133:66–76. https://doi.org/10.1016/j.jsbmb.2012.08.007
Mei Z, Yang T, Liu Y, Gao Y, Hou Z, Zhuang Q et al (2022) Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment. Cell Rep Med 3(5):100608. https://doi.org/10.1016/j.xcrm.2022.100608
Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X et al (2021) Sex hormones, insulin, and insulin-like growth factors in recurrence of high-stage endometrial cancer. Cancer Epidemiol Biomarkers Prev 30(4):719–726. https://doi.org/10.1158/1055-9965.Epi-20-1613
Michels KA, Brinton LA, Wentzensen N, Pan K, Chen C, Anderson GL et al (2019) Postmenopausal androgen metabolism and endometrial cancer risk in the Women’s Health Initiative observational study. JNCI Cancer Spectr 3(3):pkz029. https://doi.org/10.1093/jncics/pkz029
Michmerhuizen AR, Spratt DE, Pierce LJ, Speers CW (2020) ARe we there yet? Understanding androgen receptor signaling in breast cancer. NPJ Breast Cancer 6:47. https://doi.org/10.1038/s41523-020-00190-9
Miller WL, Auchus RJ (2019) The “backdoor pathway” of androgen synthesis in human male sexual development. PLoS Biol 17(4):e3000198. https://doi.org/10.1371/journal.pbio.3000198
Miller WL, Bose HS (2011) Early steps in steroidogenesis: intracellular cholesterol trafficking. J Lipid Res 52(12):2111–2135. https://doi.org/10.1194/jlr.R016675
Miricescu D, Totan A, Stanescu S II, Badoiu SC, Stefani C, Greabu M (2020) PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci 22(1). https://doi.org/10.3390/ijms22010173
Mitre-Aguilar IB, Moreno-Mitre D, Melendez-Zajgla J, Maldonado V, Jacobo-Herrera NJ, Ramirez-Gonzalez V, Mendoza-Almanza G (2022) The role of glucocorticoids in breast cancer therapy. Curr Oncol 30(1):298–314. https://doi.org/10.3390/curroncol30010024
Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK et al (2012) Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 72(23):6142–6152. https://doi.org/10.1158/0008-5472.Can-12-1335
Miyamoto H, Messing EM, Chang C (2004) Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61(4):332–353. https://doi.org/10.1002/pros.20115
Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y, Noguchi S (2001) Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int J Cancer 94(5):685–689. https://doi.org/10.1002/ijc.1525
Mizushima T, Miyamoto H (2019) The role of androgen receptor signaling in ovarian cancer. Cells 8(2). https://doi.org/10.3390/cells8020176
Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J et al (1998) Cancer incidence in a cohort of infertile women. Am J Epidemiol 147(11):1038–1042. https://doi.org/10.1093/oxfordjournals.aje.a009397
Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA et al (2015) Progesterone receptor modulates ERα action in breast cancer. Nature 523(7560):313–317. https://doi.org/10.1038/nature14583
Mørch LS, Løkkegaard E, Andreasen AH, Kjaer SK, Lidegaard O (2012) Hormone therapy and different ovarian cancers: a national cohort study. Am J Epidemiol 175(12):1234–1242. https://doi.org/10.1093/aje/kwr446
Mostaghel EA, Marck BT, Kolokythas O, Chew F, Yu EY, Schweizer MT et al (2021) Circulating and intratumoral adrenal androgens correlate with response to Abiraterone in men with castration-resistant prostate cancer. Clin Cancer Res 27(21):6001–6011. https://doi.org/10.1158/1078-0432.Ccr-21-1819
Nelles JL, Hu W-Y, Prins GS (2011) Estrogen action and prostate cancer. Exp Rev Endocrinol Metabol 6(3):437–451. https://doi.org/10.1586/eem.11.20
Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y et al (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20(1):119–131. https://doi.org/10.1016/j.ccr.2011.05.026
Nie H, Li J, Yang XM, Cao QZ, Feng MX, Xue F et al (2015) Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma. Hepatology 62(4):1145–1159. https://doi.org/10.1002/hep.27940
Nordin A, Wang W, Welén K, Damber JE (2013) Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer. Prostate 73(6):657–667. https://doi.org/10.1002/pros.22607
Noureddine LM, Trédan O, Hussein N, Badran B, Le Romancer M, Poulard C (2021) Glucocorticoid receptor: a multifaceted actor in breast cancer. Int J Mol Sci 22(9). https://doi.org/10.3390/ijms22094446
Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F et al (2022) Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(9):860–877. https://doi.org/10.1016/j.annonc.2022.05.009
Oettel M, Mukhopadhyay AK (2004) Progesterone: the forgotten hormone in men? Aging Male 7(3):236–257. https://doi.org/10.1080/13685530400004199
Ostróżka-Cieślik A, Dolińska B (2020) The role of hormones and trophic factors as components of preservation solutions in protection of renal function before transplantation: a review of the literature. Molecules 25(9). https://doi.org/10.3390/molecules25092185
Pasquali R, Oriolo C (2019) Obesity and androgens in women. Front Horm Res 53:120–134. https://doi.org/10.1159/000494908
Payne AH, Hales DB (2004) Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 25(6):947–970. https://doi.org/10.1210/er.2003-0030
Pearce CL, Chung K, Pike MC, Wu AH (2009) Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 115(3):531–539. https://doi.org/10.1002/cncr.23956
Pedram A, Razandi M, Sainson RCA, Kim JK, Hughes CC, Levin ER (2007) A conserved mechanism for steroid receptor translocation to the plasma membrane*. J Biol Chem 282(31):22278–22288. https://doi.org/10.1074/jbc.M611877200
Petrucelli N, Daly MB, Pal T (1993) BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH et al (eds) GeneReviews(®). University of Washington, Seattle. Copyright © 1993–2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved
Prange-Kiel J, Rune GM, Zwirner M, Wallwiener D, Kiesel L (2001) Regulation of estrogen receptor alpha and progesterone receptor (isoform A and B) expression in cultured human endometrial cells. Exp Clin Endocrinol Diabetes 109(4):231–237. https://doi.org/10.1055/s-2001-15111
Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L et al (2015) Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24(Suppl 2):S26–S35. https://doi.org/10.1016/j.breast.2015.07.008
Pratt WB, Toft DO (1997) Steroid receptor interactions with heat shock protein and Immunophilin chaperones*. Endocr Rev 18(3):306–360. https://doi.org/10.1210/edrv.18.3.0303
Prossnitz ER, Arterburn JB, Sklar LA (2007) GPR30: a G protein-coupled receptor for estrogen. Mol Cell Endocrinol 265-266:138–142. https://doi.org/10.1016/j.mce.2006.12.010
Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, Thompson AM (2014) Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer 110(3):565–572. https://doi.org/10.1038/bjc.2013.756
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE et al (2021) Prostate cancer. Nat Rev Dis Primers 7(1):9. https://doi.org/10.1038/s41572-020-00243-0
Rege J, Turcu AF, Kasa-Vubu JZ, Lerario AM, Auchus GC, Auchus RJ et al (2018) 11-Ketotestosterone is the dominant circulating bioactive androgen during Normal and premature Adrenarche. J Clin Endocrinol Metab 103(12):4589–4598. https://doi.org/10.1210/jc.2018-00736
Rice MS, Eliassen AH, Hankinson SE, Lenart EB, Willett WC, Tamimi RM (2016) Breast cancer research in the nurses’ health studies: exposures across the life course. Am J Public Health 106(9):1592–1598. https://doi.org/10.2105/ajph.2016.303325
Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP (2008) Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 22(5):1512–1520. https://doi.org/10.1096/fj.07-9526com
Rodriguez AC, Blanchard Z, Maurer KA, Gertz J (2019) Estrogen signaling in endometrial cancer: a Key oncogenic pathway with several open questions. Horm Cancer 10(2–3):51–63. https://doi.org/10.1007/s12672-019-0358-9
Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J (2017) The role of GATA2 in lethal prostate cancer aggressiveness. Nat Rev Urol 14(1):38–48. https://doi.org/10.1038/nrurol.2016.225
Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119–v133. https://doi.org/10.1093/annonc/mdw270
Sabharwal N, Sharifi N (2019) HSD3B1 genotypes conferring adrenal-restrictive and adrenal-permissive phenotypes in prostate cancer and beyond. Endocrinology 160(9):2180–2188. https://doi.org/10.1210/en.2019-00366
Sakellakis M, Flores LJ (2022) Is the glucocorticoid receptor a key player in prostate cancer?: a literature review. Medicine (Baltimore) 101(29):e29716. https://doi.org/10.1097/md.0000000000029716
Sasano H, Frost AR, Saitoh R, Matsunaga G, Nagura H, Krozowski ZS, Silverberg SG (1997) Localization of mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase type II in human breast and its disorders. Anticancer Res 17(3c):2001–2007
Satpathi S, Gaurkar SS, Potdukhe A, Wanjari MB (2023) Unveiling the role of hormonal imbalance in breast cancer development: a comprehensive review. Cureus 15(7):e41737. https://doi.org/10.7759/cureus.41737
Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L (2016) Hormone receptor/human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going. Cancer Treat Rev 46:20–26. https://doi.org/10.1016/j.ctrv.2016.03.012
Schlumbrecht M, Wright K, George S (2023) Unique considerations in early detection, risk, and awareness of endometrial cancer in black women. Cancer Control 30:10732748231202952. https://doi.org/10.1177/10732748231202952
Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL et al (2006) Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(1):86–91. https://doi.org/10.1158/1055-9965.Epi-05-0633
Sharifi N (2012) The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer. J Investig Med 60(2):504–507. https://doi.org/10.2310/JIM.0b013e31823874a4
Sharifi N, Auchus RJ (2012) Steroid biosynthesis and prostate cancer. Steroids 77(7):719–726. https://doi.org/10.1016/j.steroids.2012.03.015
Shen M, Demers LK, Bailey SD, Labbé DP (2022) To bind or not to bind: Cistromic reprogramming in prostate cancer. Front Oncol 12:963007. https://doi.org/10.3389/fonc.2022.963007
Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M et al (2019) Association of Missense Polymorphism in HSD3B1 with outcomes among men with prostate cancer treated with androgen-deprivation therapy or Abiraterone. JAMA Netw Open 2(2):e190115. https://doi.org/10.1001/jamanetworkopen.2019.0115
Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK (2020) Prostate cancer incidence and survival, by stage and race/ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep 69(41):1473–1480. https://doi.org/10.15585/mmwr.mm6941a1
Sikora MJ (2016) Family matters: collaboration and conflict among the steroid receptors raises a need for group therapy. Endocrinology 157(12):4553–4560. https://doi.org/10.1210/en.2016-1778
Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA, Melner MH (2005) Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev 26(4):525–582. https://doi.org/10.1210/er.2002-0050
Singhal H, Greene ME, Tarulli G, Zarnke AL, Bourgo RJ, Laine M et al (2016) Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci Adv 2(6):e1501924. https://doi.org/10.1126/sciadv.1501924
St John J, Powell K, Conley-Lacomb MK, Chinni SR (2012) TMPRSS2-ERG fusion gene expression in prostate tumor cells and its clinical and biological significance in prostate cancer progression. J Cancer Sci Ther 4(4):94–101. https://doi.org/10.4172/1948-5956.1000119
Stocco C (2012) Tissue physiology and pathology of aromatase. Steroids 77(1–2):27–35. https://doi.org/10.1016/j.steroids.2011.10.013
Storbeck K-H, Bloem LM, Africander D, Schloms L, Swart P, Swart AC (2013) 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer? Mol Cell Endocrinol 377(1):135–146. https://doi.org/10.1016/j.mce.2013.07.006
Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B et al (2008) TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27(40):5348–5353. https://doi.org/10.1038/onc.2008.183
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
Suzuki T, Miki Y, Moriya T, Akahira J, Hirakawa H, Ohuchi N, Sasano H (2007) In situ production of sex steroids in human breast carcinoma. Med Mol Morphol 40(3):121–127. https://doi.org/10.1007/s00795-007-0365-8
Takagi K, Miki Y, Nagasaki S, Hirakawa H, Onodera Y, Akahira J et al (2010) Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocr Relat Cancer 17(2):415–430. https://doi.org/10.1677/erc-09-0257
Takeshima H, Ushijima T (2019) Accumulation of genetic and epigenetic alterations in normal cells and cancer risk. Npj precision. Oncology 3(1):7. https://doi.org/10.1038/s41698-019-0079-0
Tangen IL, Onyango TB, Kopperud R, Berg A, Halle MK, Øyan AM et al (2016) Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget 7(31):49289–49298. https://doi.org/10.18632/oncotarget.10334
Thakur L, Thakur S (2023) The interplay of sex steroid hormones and microRNAs in endometrial cancer: current understanding and future directions. Front Endocrinol (Lausanne) 14:1166948. https://doi.org/10.3389/fendo.2023.1166948
Thiebaut C, Vlaeminck-Guillem V, Trédan O, Poulard C, Le Romancer M (2021) Non-genomic signaling of steroid receptors in cancer. Mol Cell Endocrinol 538:111453. https://doi.org/10.1016/j.mce.2021.111453
Tian L, Peng Y, Yang K, Cao J, Du X, Liang Z et al (2022) The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer. Cell Commun Signal 20(1):178. https://doi.org/10.1186/s12964-022-00979-0
Trabert B, Bauer DC, Buist DSM, Cauley JA, Falk RT, Geczik AM et al (2020) Association of circulating progesterone with breast cancer risk among postmenopausal women. JAMA Netw Open 3(4):e203645. https://doi.org/10.1001/jamanetworkopen.2020.3645
Treviño LS, Gorelick DA (2021) The Interface of nuclear and membrane steroid signaling. Endocrinology 162(8). https://doi.org/10.1210/endocr/bqab107
Truong TH, Lange CA (2018) Deciphering steroid receptor crosstalk in hormone-driven cancers. Endocrinology 159(12):3897–3907. https://doi.org/10.1210/en.2018-00831
Tumolo S, Rao BR, van der Burg ME, Guastalla JP, Renard J, Vermorken JB (1994) Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological cancer cooperative group study. Eur J Cancer 30a(7):911–914. https://doi.org/10.1016/0959-8049(94)90112-0
Turcu AF, Nanba AT, Chomic R, Upadhyay SK, Giordano TJ, Shields JJ et al (2016) Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. Eur J Endocrinol 174(5):601–609. https://doi.org/10.1530/eje-15-1181
Unluhizarci K, Karaca Z, Kelestimur F (2021) Role of insulin and insulin resistance in androgen excess disorders. World J Diabetes 12(5):616–629. https://doi.org/10.4239/wjd.v12.i5.616
Vahrenkamp JM, Yang CH, Rodriguez AC, Almomen A, Berrett KC, Trujillo AN et al (2018) Clinical and genomic crosstalk between glucocorticoid receptor and estrogen receptor α in endometrial cancer. Cell Rep 22(11):2995–3005. https://doi.org/10.1016/j.celrep.2018.02.076
Valko-Rokytovská M, Očenáš P, Salayová A, Kostecká Z (2021) Breast cancer: targeting of steroid hormones in Cancerogenesis and diagnostics. Int J Mol Sci 22(11). https://doi.org/10.3390/ijms22115878
Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Pateras H, Efremidis AP (2000) Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann Oncol 11(9):1155–1160. https://doi.org/10.1023/a:1008377724931
Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR et al (2017) High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol 146(1):153–160. https://doi.org/10.1016/j.ygyno.2017.04.012
Wang Y, Romigh T, He X, Tan MH, Orloff MS, Silverman RH et al (2011) Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 30(42):4327–4338. https://doi.org/10.1038/onc.2011.144
Wend K, Wend P, Krum SA (2012) Tissue-specific effects of loss of estrogen during menopause and aging. Front Endocrinol (Lausanne) 3:19. https://doi.org/10.3389/fendo.2012.00019
Whiteman DC, Siskind V, Purdie DM, Green AC (2003) Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 12(1):42–46
Wilkenfeld SR, Lin C, Frigo DE (2018) Communication between genomic and non-genomic signaling events coordinate steroid hormone actions. Steroids 133:2–7. https://doi.org/10.1016/j.steroids.2017.11.005
Wilson JD, Auchus RJ, Leihy MW, Guryev OL, Estabrook RW, Osborn SM et al (2003) 5alpha-androstane-3alpha,17beta-diol is formed in tammar wallaby pouch young testes by a pathway involving 5alpha-pregnane-3alpha,17alpha-diol-20-one as a key intermediate. Endocrinology 144(2):575–580. https://doi.org/10.1210/en.2002-220721
Wu S, Yu K, Lian Z, Deng S (2022) Molecular regulation of androgen receptors in major female reproductive system cancers. Int J Mol Sci 23(14). https://doi.org/10.3390/ijms23147556
**ao L, Feng Q, Zhang Z, Wang F, Lydon JP, Ittmann MM et al (2016) The essential role of GATA transcription factors in adult murine prostate. Oncotarget 7(30):47891–47903. https://doi.org/10.18632/oncotarget.10294
**e N, Cheng H, Lin D, Liu L, Yang O, Jia L et al (2015) The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer 136(4):E27–E38. https://doi.org/10.1002/ijc.29147
Xu Z, Wang Y, **ao ZG, Zou C, Zhang X, Wang Z et al (2018) Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer. Oncogene 37(48):6259–6274. https://doi.org/10.1038/s41388-018-0409-7
Xu S, Yu S, Dong D, Lee LTO (2019) G protein-coupled estrogen receptor: a potential therapeutic target in cancer. Front Endocrinol (Lausanne) 10:725. https://doi.org/10.3389/fendo.2019.00725
Yager, J. D. (2015). Mechanisms of estrogen carcinogenesis: The role of E2/E1-quinone metabolites suggests new approaches to preventive intervention--A review. Steroids, 99(Pt A), 56–60. doi:https://doi.org/10.1016/j.steroids.2014.08.006
Yang F, Ma Q, Liu Z, Li W, Tan Y, ** C et al (2017) Glucocorticoid receptor:MegaTrans switching mediates the repression of an ERα-regulated transcriptional program. Mol Cell 66(3):321–331.e6. https://doi.org/10.1016/j.molcel.2017.03.019
Yasumizu Y, Rajabi H, ** C, Hata T, Pitroda S, Long MD et al (2020) MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun 11(1):338. https://doi.org/10.1038/s41467-019-14219-6
Yu S, Lee M, Shin S, Park J (2001) Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. J Cell Biochem 82(3):445–451. https://doi.org/10.1002/jcb.1171
Yu K, Huang ZY, Xu XL, Li J, Fu XW, Deng SL (2022) Estrogen receptor function: impact on the human endometrium. Front Endocrinol (Lausanne) 13:827724. https://doi.org/10.3389/fendo.2022.827724
Zhang L, Barritt GJ (2004) Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells. Cancer Res 64(22):8365–8373. https://doi.org/10.1158/0008-5472.Can-04-2146
Zhang C, Marmé A, Wenger T, Gutwein P, Edler L, Rittgen W et al (2006) Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int J Oncol 28(2):551–558
Zhang C, Wenger T, Mattern J, Ilea S, Frey C, Gutwein P et al (2007) Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther 6(2):278–287. https://doi.org/10.4161/cbt.6.2.3652
Zhou Y, Liu X (2020) The role of estrogen receptor beta in breast cancer. Biomark Res 8(1):39. https://doi.org/10.1186/s40364-020-00223-2
Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, Wang B (2008) Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 108(3):641–651. https://doi.org/10.1016/j.ygyno.2007.12.003
Zhou F, Gao S, Han D, Han W, Chen S, Patalano S et al (2019) TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells. Oncogene 38(22):4397–4411. https://doi.org/10.1038/s41388-019-0730-9
Zubeldia-Brenner L, Roselli CE, Recabarren SE, Gonzalez Deniselle MC, Lara HE (2016) Developmental and functional effects of steroid hormones on the neuroendocrine axis and spinal cord. J Neuroendocrinol 28(7). https://doi.org/10.1111/jne.12401
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Li, M., Li, J. (2024). Steroids in Cancer: Mechanisms, Therapies, and Challenges in Hormone-Driven Malignancies. In: Interdisciplinary Cancer Research. Springer, Cham. https://doi.org/10.1007/16833_2024_294
Download citation
DOI: https://doi.org/10.1007/16833_2024_294
Published:
Publisher Name: Springer, Cham